Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function.

ABSTRACT:

Purpose

The purpose of this study was to investigate immunological variations between a group that received the hepatitis B vaccine and a non-vaccine group. We focused on a cohort that achieved HBsAg seroclearance after Peg-IFNα treatment of CHB.

Methods

We enrolled twenty-eight individuals who achieved HBsAg seroclearance after Peg-IFNα treatment. They were divided into two groups: a vaccine group (n = 14) and a non-vaccine group (n = 14). We assessed lymphocyte subpopulations, B cell- and T cell-surface costimulatory/inhibitory factors, cytokines and immunoglobulin levels were detected at different time points to explore immune-function differences between both groups.

Results

The seroconversion rate in the vaccine group at 24 weeks post-vaccination was 100%, which

SUBMITTER: Liu Y 

PROVIDER: S-EPMC10981809 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature